Scancell Share Discussion Threads

[888icb] 18/9/2023 08:33

SCLP Up 15.1% on volume of 573000. A very promising start to the week.

[marcusl2] 18/9/2023 08:30

Prof Lindy Durrant, Chief Executive Officer and Chief Scientific Officer of Scancell, commented: "We look forward to presenting at such a prestigious meeting and sharing data on our preclinical programmes with the scientific community. As previously disclosed in a recent business update , we continue to make great progress in the clinic with our two lead cancer vaccine assets SCIB1/iSCIB-1+ and Modi-1 currently in Phase 1/2 clinical trials as well as leveraging the value of our antibody platform to generate revenue through high value licence agreements.

"Showcasing the potential of our technology platforms to generate further pipeline assets with high value partnering opportunities, we will be presenting encouraging data on both the Moditope(R) and GlyMab(R) platforms. Data on antibody candidates derived from the GlyMab(R) platform illustrate the potential of these assets as chimeric antigen receptor T cell (CAR-T) therapies and could lead to out licensing opportunities with cell therapy companies. Furthermore, we will be presenting data bolstering the potential of Modi-2 as a solid tumour cancer therapy and further characterising the response to Moditope(R) peptides in preclinical studies."

Scib-1 on 19th October.

"Showcasing the potential of our technology platforms to generate further pipeline assets with HIGH value partnering opportunities, we will be presenting ENCOURAGING data on both the Moditope and Glymab platforms"

Seventh International Cancer Immunotherapy Conference taking place on 20-23 September in Milan, Italy.

[marcusl2] 18/9/2023 08:27

SCIB1 – Phase 1/2 reduced recurrence and turned cancer into a chronic disease
88% of patients remained disease-free for 5+ years

With the addition of doublet CPI we have improved that. iScib+ will further improve the treatment.

Modi-1 is working. We are early days in the Modi-1 HIGH DOSE plus CPI
Modi-2

SC129
• Pancreatic cancer (deal done with Genmab up to $624m and single digit
royalties) We retain rights to license to a Car T company.

SC134
• Small cell lung cancer

SC2811
• Any solid tumour, iSC2811 enhances T cell engraftment and prevents exhaustion
Potential for improving CAR-T approaches

SC88
• Colorectal cancer

SC27 • Lewisy
• Ovarian cancer

Avidimab is being proven, could be huge.

Now a 5th company is assessing an antibody.

Data pack is ready for deals with the Glymabs as Car Ts.

Updates on SCIB1 and Modi-1 will be presented at the AACR-CIMT meeting in Milan in September 2023.

[rogerbridge] 18/9/2023 08:18

Thanks for the information Marcus, the DKFZ article was very interesting. SCLP looking perky.

[miavoce] 17/9/2023 07:45

Thanks inanaco and Marcus

[inanaco] 16/9/2023 21:23

its the moditope platform ........ has an effect on Lap suppressor t cells .......

that is why i did the write up after it was released read my history on day of RNS

[marcusl2] 16/9/2023 21:19

Miavoce, I am no expert but it will be about the TME (tumour micro environment). The poster may enlighten us further.

I think LAPHi MCs (myeloid cells) promote Treg accumulation and tumour growth. Maybe Inan or Burble have a better idea.

The Th1 subset of CD4+ T cells secretes cytokines usually associated with inflammation, such as IFN-gamma and TNF and induces cell-mediated immune responses. The Th2 subset produces cytokines such as IL-4 and IL-5 that help B cells to proliferate and differentiate and is associated with humoral-type immune responses.

What are the three main types of effector T cells and their functions?
Effector T cells
Regulatory T cells. Regulatory T (Treg) cells (suppressor T cells) are essential for the maintenance of immune tolerance. ...
Helper T cells. T helper cells (Th cells) help other leukocytes in immunologic processes, including maturation of B cells into plasma cells and memory B cells. ...
Cytotoxic T cells.

[miavoce] 16/9/2023 20:55

Can anybody explain what poster 2 is about - poster 1 is about the CAR-T potential of the glycans, poster 3 is about Modi-2 but which platform does poster 2 relate to ?

Poster 2
Poster presentation title : Vaccination stimulating post-translational modification specific Th1 responses repolarises the tumour environment to reduce suppressive LAP expressing T cells

[the real lozan] 15/9/2023 17:14

It is to be hoped those 'forces' preparing for war, have all been vaccinated

[inanaco] 15/9/2023 17:02

Azerbaijani forces using Russian-style symbols are massing on the border of Armenia
Open-source intelligence appears to back up Armenian claims that Azerbaijan is building up its border forces and is preparing for war

[inanaco] 15/9/2023 16:44

"missing also a Partnership"

[inanaco] 15/9/2023 16:42

"" It's all about whether or not the current trials can generate data that is good enough to secure a licensing deal or outright sale.""


Genmab ... didn't have any of that data

ATB

[marcusl2] 15/9/2023 16:32

I absolutely agree Bermuda. I simply copied the article. You generally find these reporters do not know as much about the companies as us long term devotees.

If the data is good then deals with follow. We may have a better idea by the end of OCT.

[bermudashorts] 15/9/2023 16:26

marcus,

Re. your 5749, perhaps some more research required. It's absolutely impossible for either Modi-1 or SCIB1 to reach the market by 2024. Even if recruitment suddenly increased to warp speed and results for existing trials were stunning, they both need further, much larger controlled clinical trials and are years away from the market.

IMO the investment case here is not and never has been about Scancell taking products to market. They aren't resourced or geared up to do that. It's all about whether or not the current trials can generate data that is good enough to secure a licensing deal or outright sale.

[marcusl2] 15/9/2023 16:02

Byung-June Park
@onco_park
·
8h
Replying to
@onco_park
Anti-fucosyl-GM1, #SCLC #Scancell

Conclusions
BMS-986012 in combination with nivolumab represents a well-tolerated, potential new therapy for relapsed or refractory SCLC. BMS-986012 is currently being explored in combination with carboplatin, etoposide, and nivolumab as a first-line therapy in extensive-stage SCLC (NCT04702880).


Byung-June Park
@onco_park
·
9h
6> BMS-986012, anti-fucosyl-GM1 antibody. #SCLC
The drug's efficacy when used alone is limited, but it shows promising results when combined with nivolumab.
Ref: [...]

[marcusl2] 15/9/2023 15:54

Jon Smith
4 August 2023

Waiting for a move
The other penny stock that I’m looking at is Scancell Holdings (LSE:SCLP). The stock has fallen by 24% over the past year, with a share price of just 9.5p.

The company is a clinical stage biopharmaceutical company. Ideally, it needs to be able to take products from research stage, through clinical trials and get them all approved in order to generate sizeable profits.

Currently, the business is loss-making. It doesn’t have any revenue coming in through the door, but has sizeable expenses to fund the research and trials. Although this is a risk, it’s the same practice that all in the same business line go through.

Yet on the other hand, it has £24m cash on hand (as of the latest report). It burned through £4.4m in the previous six months, so it has a big buffer to keep running operations for a while.

In the meantime, I believe it has a good shot at taking either Modi-1 or SCIB1 products to the market in 2024. Modi-1 had a recent 44% disease control rate with test patients of aggressive cancer that had exhausted other options. This shows me that the potential take-up of the product if it reaches the market could be very large. As soon as investors get a smell that this could be the case, I’d expect the share price to rally.

I’m considering investing a small amount of money in both stocks in coming weeks. I’m using a small amount due to the high risk involved. Yet if either replicate the performance of RC365, even a modest sum would be able to generate a healthy return.

[marcusl2] 15/9/2023 14:34

Scib-1 on 19th October.

"Showcasing the potential of our technology platforms to generate further pipeline assets with HIGH value partnering opportunities, we will be presenting ENCOURAGING data on both the Moditope and Glymab platforms"

Seventh International Cancer Immunotherapy Conference taking place on 20-23 September in Milan, Italy.

[markingtime] 15/9/2023 14:06

Mental......

[markingtime] 15/9/2023 11:33

The difference between now and the past decade is that we know that progress is being made on multiple fronts. Never quickly enough, of course, but there is now much more than mere hope behind the trailers - not least because we know that trials are active.The novel aspect to the Modi trial is the tumour resections - and that will give considerable help to the research, I think.Meanwhile the pancreatic deal with Genmab should be due for an update from them soon, I suspect.

[markingtime] 15/9/2023 11:25

Drivel. As usual.